| Species |
Mouse |
| Protein Construction |
APLN (Val23-Phe77)_x000D_
Accession # Q9R0R4 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
33 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS, 200mM Arginine (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Macrophages play key roles during cardiovascular diseases (CVD) and their related complications.Apelin (APLN) is a key molecule, whose roles during CVD have been documented previously. Therefore, it has been hypothesized that APLN may perform its roles via modulation of macrophages. Additionally, due to the widespread distribution of the CVD, more effective therapeutic strategies need to be developed to overcome the related complications. |
| Synonyms |
Apelin;APJ endogenous ligand;APEL |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
